Permanence Bio is a preclinical-stage company developing small molecule therapeutics that block DNA damage. Our company platform has identified two compounds that are capable of preventing DNA damage in diverse cell types across a variety of unique DNA damaging agents. We are moving these drug candidates forward into in vivo efficacy studies for familial adenomatous polyposis and dry acute macular degeneration.